No Data
No Data
Alterity Therapeutics Announced That The Last Patient In The ATH434-201 Phase 2 Trial, A Randomized, Double-blind, Placebo-controlled Investigation In Early-stage Multiple System Atrophy, Has Completed The Study And Topline Results Are Expected To Be...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Alterity Therapeutics Alerts Investors on Potential Risks
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
Alterity Therapeutics Appoints New Company Secretary
Alterity Therapeutics Unveils New Advances for MSA Tracking